OncoCyte Corporation (OCX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.3880 |
| Open | 0.3700 |
| Bid | 0.3730 x 4000 |
| Ask | 0.4000 x 800 |
| Day's Range | 0.3700 - 0.4000 |
| 52 Week Range | 0.2420 - 1.7500 |
| Volume | |
| Avg. Volume | 396,659 |
| Market Cap | 46.271M |
| Beta (5Y Monthly) | 1.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7710 |
| Earnings Date | Mar 08, 2023 - Mar 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.83 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for OCX
Related Research
- OncoCyte CorporationDaily – Vickers Top Insider Picks for 09/27/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat4 months agoArgus Research
- MarketWatch
Oncocyte cuts 40% of staff
Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its team towards key products that address larger markets." As of Dec. 31, 2021, the company employed full-time 110 people, according to Oncocyte's annual report. The positions of Gisela Paulsen, president and chief operating Officer, and Douglas Ross, chief scientific officer, will be eliminated. Onco
- GlobeNewswire
Oncocyte Announces Initiatives to Focus Corporate Strategy
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte’s workforce to realign its team towards key products that address larger markets. Additionally, Oncocyte has entered into a Stock Purchase Agreement pursuant to which Oncocyte will transfer 70% of its ownership of Razor Genomics, Inc. to buyers who are leaders in the development of early stage lung cancer diagno
- GlobeNewswire
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of Louis E. Silverman as an independent member of its board of directors, effective immediately. “I am pleased to announce the appointment of Lou as a member of our Board,” said Andy Arno, Chair of Onco
